Lupus enteritis is a rare gastrointestinal complication of systemic lupus erythematosus (SLE) associated with significant morbidity and mortality. Rituximab, a monoclonal antibody targeting CD20-positive B cells, has shown promise in refractory SLE cases. We present a case of a 45-year-old female with SLE who developed lupus enteritis and experienced an unusually rapid and remarkable response to Rituximab. The patient presented with severe abdominal pain and distension. Within two days of Rituximab treatment, the patient's abdominal pain, distension, and associated complications resolved completely. This exceptional response challenges the typical timeline of Rituximab efficacy in SLE and highlights the need for further investigation into the factors influencing treatment response. Understanding the mechanisms underlying such rapid improvement may provide insights into SLE pathogenesis and guide therapeutic strategies for optimal outcomes.

Cite this article as: Hussein AH, Altamimi BL. Rapid and Remarkable Response to Rituximab in a Case of Lupus Enteritis: Challenging the Norm. Mediterr J Rheumatol 2024;35(1):187-91.

Article Submitted: 9 Jun 2023; Revised Form: 26 Sep 2023; Article Accepted: 10 Oct 2023; Available Online: 08 Jun 2024

This work is licensed under a Creative Commons Attribution 4.0 International License.

©2024 The Author(s).

https://doi.org/10.31138/mjr.080624.rar